Summary
Regeneron Pharmaceuticals, Inc. reported strong financial performance for the nine months ended September 30, 2020, with total revenues increasing by 29% year-over-year to $6.1 billion and net income growing by 79% to $2.4 billion. This growth was driven by robust net product sales, particularly from EYLEA and Dupixent, and significant increases in collaboration revenue, notably from Sanofi. The company also made substantial investments in research and development, reflecting its commitment to pipeline expansion, including significant progress on REGN-COV2, its antibody cocktail for COVID-19. Financially, Regeneron maintained a strong liquidity position with over $1.5 billion in cash and cash equivalents and over $4.3 billion in marketable securities as of September 30, 2020. The company also successfully raised $2 billion in senior unsecured notes in August 2020 to support its operations. Despite ongoing patent litigation and regulatory scrutiny, particularly concerning Praluent and Eylea, Regeneron demonstrated resilience and continued growth, underscoring its strong market position and product pipeline.
Financial Highlights
44 data points| Revenue | $2.29B |
| R&D Expenses | $684.60M |
| SG&A Expenses | $326.90M |
| Operating Expenses | $1.24B |
| Operating Income | $1.05B |
| Interest Expense | $26.30M |
| Net Income | $842.10M |
| EPS (Basic) | $7.98 |
| EPS (Diluted) | $7.39 |
| Shares Outstanding (Basic) | 105.50M |
| Shares Outstanding (Diluted) | 113.90M |
Key Highlights
- 1Total revenues for the nine months ended September 30, 2020, increased by 29% to $6.1 billion, compared to $4.7 billion in the prior year period.
- 2Net income for the nine months ended September 30, 2020, increased by 79% to $2.4 billion, or $20.36 per diluted share, compared to $1.3 billion, or $11.54 per diluted share, in the prior year period.
- 3Net product sales for the nine months ended September 30, 2020, increased by 21% to $10.1 billion, primarily driven by strong performance in EYLEA and Dupixent.
- 4Sanofi collaboration revenue saw a significant increase of 271% to $869 million for the nine months ended September 30, 2020, primarily due to higher profit sharing on antibodies and a $50 million sales milestone.
- 5The company made a significant $5 billion stock purchase from Sanofi in May 2020 and repaid its $1.5 billion bridge loan facility.
- 6Regeneron advanced its COVID-19 antibody cocktail, REGN-COV2, into late-stage clinical trials and submitted for Emergency Use Authorization (EUA) in October 2020.
- 7Research and development expenses increased by 5% to $2.0 billion for the nine months ended September 30, 2020, reflecting ongoing investments in pipeline development.